China and the United States are beginning to slowly reopen while continuing to deal with the devastating impact of the virus. But there’s some promising news about a potential treatment for COVID-19. The U.S. has approved the use of the antiviral drug Remdesivir to treat certain coronavirus patients.
To discuss the ongoing medical and economic challenges:
- Dr. Michael Saag is Associate Dean for Global Health at The University of Alabama at Birmingham.
- Victor Gao is Vice President of the Center for China and Globalization.
- Joseph Williams is Senior News Editor at U.S. News & World Report.
- Arthur Dong is a professor at Georgetown University’s McDonough School of Business.
At $4,500 for a round of treatment for remdesivir, Gilead’s new Covid-19 medicine could generate over $2 billion in revenue, even after a promise to give away the first 1.5 million vials https://t.co/mkEjqmLaht
— Bloomberg (@business) May 4, 2020
The FDA issued emergency approval for the medicine, which may help hospitalized COVID-19 patients recover. https://t.co/P36JxxnEee
— HuffPost Life (@HuffPostLife) May 2, 2020
— Scientific American (@sciam) May 1, 2020